

6841561

FILE 'REGISTRY' ENTERED AT 16:13:23 ON 13 NOV 2007
EXP MIZORIBINE/CN

L1 1 S E3
L2 0 S MYCOPHENOL/CN
EXP MYCOPHENOL/CN
EXP MYCOPHENOLATE SODIUM/CN
L3 11 S E1-E12
EXP MYCOPHENOLIC ACID METHYL ESTER/CN
EXP TIAZOFURIN/CN
L4 1 S E3
L5 1 S RIBAVIRIN/CN

FILE 'STNGUIDE' ENTERED AT 16:15:43 ON 13 NOV 2007

FILE 'HCAPLUS' ENTERED AT 16:18:59 ON 13 NOV 2007

L6 7877 S L1 OR L3-L5
L7 263 S (IMPDH OR (INOSINE MONOPHOSPHATE DEHYDROGENASE)) (2A) INHIBIT?
L8 607 S (INDUC(3A)INTERFERON) OR (CPG NUCLEOTIDE) OR ((TLR OR (TOLL-L
L9 790563 S CANCER OR TUMOR OR NEOPLAS?
L10 1002 S L6 AND L9
L11 70 S L7 AND L9
L12 267 S L8 AND L9
L13 2 S (L6 OR L7) AND L8
L14 2 S L13 AND L9

FILE 'STNGUIDE' ENTERED AT 16:19:11 ON 13 NOV 2007

FILE 'HCAPLUS' ENTERED AT 16:20:15 ON 13 NOV 2007

L15 594 S L10 AND (PY<2003 OR AY<2003 OR PRY<2003)
L16 49 S L11 AND (PY<2003 OR AY<2003 OR PRY<2003)
L17 23 S L12 AND (PY<2003 OR AY<2003 OR PRY<2003)
L18 0 S L13 AND (PY<2003 OR AY<2003 OR PRY<2003)
L19 0 S L14 AND (PY<2003 OR AY<2003 OR PRY<2003)

FILE 'HCAPLUS' ENTERED AT 16:23:33 ON 13 NOV 2007

L20 17277 S INDUC?(3A)INTERFERON
L21 594 S L15 AND L9
L22 0 S L15 AND L8
L23 49 S L16 AND (PY<2003 OR AY<2003 OR PRY<2003)
L24 23 S L17 AND (PY<2003 OR AY<2003 OR PRY<2003)

FILE 'STNGUIDE' ENTERED AT 16:23:43 ON 13 NOV 2007

FILE 'HCAPLUS' ENTERED AT 16:24:53 ON 13 NOV 2007

L25 4720 S L20 AND L9
L26 59 S L20 AND L8
L27 2959 S L25 AND (PY<2003 OR AY<2003 OR PRY<2003)
L28 6 S L26 AND (PY<2003 OR AY<2003 OR PRY<2003)

FILE 'HCAPLUS' ENTERED AT 16:28:38 ON 13 NOV 2007

L29 2 S L20 AND L7
L30 0 S L29 AND (PY<2003 OR AY<2003 OR PRY<2003)

FILE 'HCAPLUS' ENTERED AT 17:00:10 ON 13 NOV 2007

L31 21 S ((INOSINE MONOPHOSPHATE DEHYDROGENASE)OR(IMPDH)) AND INTERFER

FILE 'STNGUIDE' ENTERED AT 17:00:26 ON 13 NOV 2007

FILE 'HCAPLUS' ENTERED AT 17:01:36 ON 13 NOV 2007

L32 9 S L31 AND (PY<2004 OR AY<2004 OR PRY<2004)

FILE 'HCAPLUS' ENTERED AT 17:06:48 ON 13 NOV 2007

L33
L34

58 S ((INOSINE MONOPHOSPHATE DEHYDROGENASE) OR (IMPDH)) AND INTERFER
10 S ((INOSINE MONOPHOSPHATE DEHYDROGENASE) OR (IMPDH)) AND INTERFER

=> file registry		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:13:23 ON 13 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 12 NOV 2007 HIGHEST RN 953132-99-5
DICTIONARY FILE UPDATES: 12 NOV 2007 HIGHEST RN 953132-99-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> exp mizoribine/cn

E1	1	MIZOLIN/CN
E2	1	MIZONIDAZOLE/CN
E3	1 -->	MIZORIBINE/CN
E4	1	MIZORIBINE 5'-MONOPHOSPHATE/CN
E5	1	MIZUACE/CN
E6	1	MIZUCRIN L 401/CN
E7	1	MIZUFLOK 5000/CN
E8	1	MIZUFLOK 630/CN
E9	1	MIZUFLOK 700/CN
E10	1	MIZUFLOK 730/CN
E11	1	MIZUFLOK 760/CN
E12	1	MIZUFLOK 800/CN

=> s E3

L1	1	MIZORIBINE/CN
----	---	---------------

=> s mycophenol/cn

L2	0	MYCOPHENOL/CN
----	---	---------------

=> exp mycophenol/cn

E1	1	MYCOPENTENE 1/CN
E2	1	MYCOPENTENE 2/CN
E3	0 -->	MYCOPHENOL/CN
E4	1	MYCOPHENOLAMIDE/CN
E5	1	MYCOPHENOLATE MOFETIL/CN
E6	1	MYCOPHENOLATE MOFETIL HYDROCHLORIDE/CN
E7	1	MYCOPHENOLATE SODIUM/CN
E8	1	MYCOPHENOLIC ACID/CN
E9	1	MYCOPHENOLIC ACID 2,2,2-TRICHLOROETHYL ESTER/CN
E10	1	MYCOPHENOLIC ACID 2,2,2-TRIFLUOROETHYL ESTER/CN
E11	1	MYCOPHENOLIC ACID ACETATE/CN
E12	1	MYCOPHENOLIC ACID CHLORIDE/CN

=> exp mycophenolate sodium/cn

E1 1 MYCOPHENOLATE MOFETIL/CN
E2 1 MYCOPHENOLATE MOFETIL HYDROCHLORIDE/CN
E3 1 --> MYCOPHENOLATE SODIUM/CN
E4 1 MYCOPHENOLIC ACID/CN
E5 1 MYCOPHENOLIC ACID 2,2,2-TRICHLOROETHYL ESTER/CN
E6 1 MYCOPHENOLIC ACID 2,2,2-TRIFLUOROETHYL ESTER/CN
E7 1 MYCOPHENOLIC ACID ACETATE/CN
E8 1 MYCOPHENOLIC ACID CHLORIDE/CN
E9 1 MYCOPHENOLIC ACID DISODIUM SALT/CN
E10 1 MYCOPHENOLIC ACID GLUCOSIDURONATE/CN
E11 1 MYCOPHENOLIC ACID GLUCURONIDE/CN
E12 1 MYCOPHENOLIC ACID METHYL ESTER/CN

=> s E1-E12

1 "MYCOPHENOLATE MOFETIL"/CN
1 "MYCOPHENOLATE MOFETIL HYDROCHLORIDE"/CN
1 "MYCOPHENOLATE SODIUM"/CN
1 "MYCOPHENOLIC ACID"/CN
1 "MYCOPHENOLIC ACID 2,2,2-TRICHLOROETHYL ESTER"/CN
1 "MYCOPHENOLIC ACID 2,2,2-TRIFLUOROETHYL ESTER"/CN
1 "MYCOPHENOLIC ACID ACETATE"/CN
1 "MYCOPHENOLIC ACID CHLORIDE"/CN
1 "MYCOPHENOLIC ACID DISODIUM SALT"/CN
1 "MYCOPHENOLIC ACID GLUCOSIDURONATE"/CN
1 "MYCOPHENOLIC ACID GLUCURONIDE"/CN
1 "MYCOPHENOLIC ACID METHYL ESTER"/CN
L3 11 ("MYCOPHENOLATE MOFETIL"/CN OR "MYCOPHENOLATE MOFETIL HYDROCHLORIDE"/CN OR "MYCOPHENOLATE SODIUM"/CN OR "MYCOPHENOLIC ACID"/CN OR "MYCOPHENOLIC ACID 2,2,2-TRICHLOROETHYL ESTER"/CN OR "MYCOPHENOLIC ACID 2,2,2-TRIFLUOROETHYL ESTER"/CN OR "MYCOPHENOLIC ACID ACETATE"/CN OR "MYCOPHENOLIC ACID CHLORIDE"/CN OR "MYCOPHENOLIC ACID DISODIUM SALT"/CN OR "MYCOPHENOLIC ACID GLUCOSIDURONATE"/CN OR "MYCOPHENOLIC ACID GLUCURONIDE"/CN OR "MYCOPHENOLIC ACID METHYL ESTER"/CN)

=> exp mycophenolic acid methyl ester/cn

E1 1 MYCOPHENOLIC ACID GLUCOSIDURONATE/CN
E2 1 MYCOPHENOLIC ACID GLUCURONIDE/CN
E3 1 --> MYCOPHENOLIC ACID METHYL ESTER/CN
E4 1 MYCOPHENOLIC ACID MONOAMMONIUM SALT/CN
E5 1 MYCOPHENOLIC ACID MONOSODIUM SALT/CN
E6 1 MYCOPHENOLIC ACID RESISTANCE PROTEIN (SYNTHETIC PLASMID VECTOR PPZ3TA GENE IMH3)/CN
E7 1 MYCOPHENOLIC MONOSODIUM SALT/CN
E8 1 MYCOPHYT/CN
E9 1 MYCOPLANECIN A/CN
E10 1 MYCOPLANECIN A, 1-(6-CARBOXYLYSINE)-/CN
E11 1 MYCOPLANECIN A, 1-(N-((1,1-DIMETHYLETHOXY)CARBONYL)-L-ASPARTIC ACID)-, PHENYLMETHYL ESTER/CN
E12 1 MYCOPLANECIN A, 1-(N-((1,1-DIMETHYLETHOXY)CARBONYL)-L-CYSTEINE)-, (1.FWDARW.2')-DISULFIDE WITH L-Γ-GLUTAMYL-L-CYSTEINYLGLYCINE/CN

=> exp tiazofurin/cn

E1 1 TIAZESIM/CN
E2 1 TIAZESIM HYDROCHLORIDE/CN
E3 1 --> TIAZOFURIN/CN
E4 1 TIAZOFURIN 5'-DIPHOSPHATE/CN
E5 1 TIAZOFURIN 5'-MONOPHOSPHATE/CN
E6 1 TIAZOFURIN 5'-TRIPHOSPHATE/CN
E7 1 TIAZOFURINE/CN
E8 1 TIAZOL 2MBS/CN
E9 1 TIAZOLIDIN/CN

E10 1 TIAZURIL/CN
E11 1 TIAZURIL SULFONE/CN
E12 1 TIAZURIL SULFOXIDE/CN

=> s E3

L4 1 TIAZOFURIN/CN

=> s ribavirin/cn

L5 1 RIBAVIRIN/CN

=> file stnguide

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

81.00

81.21

FILE 'STNGUIDE' ENTERED AT 16:15:43 ON 13 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Nov 9, 2007 (20071109/UP).

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.30

81.51

FILE 'HCAPLUS' ENTERED AT 16:18:59 ON 13 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Nov 2007 VOL 147 ISS 21
FILE LAST UPDATED: 12 Nov 2007 (20071112/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s L1 or L3-L5

440 L1

3828 L3

385 L4

3592 L5

L6 7877 L1 OR (L3 OR L4 OR L5)

=> s (IMPDH or (inosine monophosphae dehydrogenase))(2a)inhibit?

470 IMPDH

11564 INOSINE

3 MONOPHOSPHAE

```

171702 DEHYDROGENASE
  1 INOSINE MONOPHOSPHAE DEHYDROGENASE
    (INOSINE (W) MONOPHOSPHAE (W) DEHYDROGENASE)
1978251 INHIBIT?
L7      263 (IMPDH OR (INOSINE MONOPHOSPHAE DEHYDROGENASE)) (2A) INHIBIT?

=> s (induc(3a)interferon) or (CPG nucleotide) or ((TLR or (toll-like
receptor)) (2a) (ligand or activator or agonist))

      2 INDUC
      79949 INTERFERON
        0 INDUC(3A) INTERFERON
      13064 CPG
      456511 NUCLEOTIDE
        8 CPG NUCLEOTIDE
          (CPG(W) NUCLEOTIDE)
      7886 TLR
      9958 TOLL
      826574 LIKE
      725174 RECEPTOR
        7434 TOLL-LIKE RECEPTOR
          (TOLL(W) LIKE(W) RECEPTOR)
      331941 LIGAND
      110453 ACTIVATOR
      115175 AGONIST
        599 (TLR OR (TOLL-LIKE RECEPTOR)) (2A) (LIGAND OR ACTIVATOR OR AGONIST
          )
L8      607 (INDUC(3A) INTERFERON) OR (CPG NUCLEOTIDE) OR ((TLR OR (TOLL-LIKE
RECEPTOR)) (2A) (LIGAND OR ACTIVATOR OR AGONIST))

```

=> s cancer or tumor or neoplas?

```

      336770 CANCER
      428563 TUMOR
      517459 NEOPLAS?
L9      790563 CANCER OR TUMOR OR NEOPLAS?

```

=> s 16 and 19

```

L10      1002 L6 AND L9

```

=> s 17 and 19

```

L11      70 L7 AND L9

```

=> s 18 and 19

```

L12      267 L8 AND L9

```

=> s (16 or 17) and 18

```

L13      2 (L6 OR L7) AND L8

```

=> s 113 and 19

```

L14      2 L13 AND L9

```

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.60	84.11

FILE 'STNGUIDE' ENTERED AT 16:19:11 ON 13 NOV 2007

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Nov 9, 2007 (20071109/UP).

=> file hcaplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.12	84.23

FILE 'HCAPLUS' ENTERED AT 16:20:15 ON 13 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Nov 2007 VOL 147 ISS 21
FILE LAST UPDATED: 12 Nov 2007 (20071112/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l10 and (PY<2003 or AY<2003 or PRY<2003)

```
      22908320 PY<2003
      4466789 AY<2003
      3945652 PRY<2003
L15      594 L10 AND (PY<2003 OR AY<2003 OR PRY<2003)
```

=> s l11 and (PY<2003 or AY<2003 or PRY<2003)

```
      22908320 PY<2003
      4466789 AY<2003
      3945652 PRY<2003
L16      49 L11 AND (PY<2003 OR AY<2003 OR PRY<2003)
```

=> s l12 and (PY<2003 or AY<2003 or PRY<2003)

```
      22908320 PY<2003
      4466789 AY<2003
      3945652 PRY<2003
L17      23 L12 AND (PY<2003 OR AY<2003 OR PRY<2003)
```

=> s l13 and (PY<2003 or AY<2003 or PRY<2003)

```
      22908320 PY<2003
      4466789 AY<2003
      3945652 PRY<2003
L18      0 L13 AND (PY<2003 OR AY<2003 OR PRY<2003)
```

=> s l14 and (PY<2003 or AY<2003 or PRY<2003)

22908320 PY<2003
4466789 AY<2003
3945652 PRY<2003

L19 0 L14 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.60	86.83

FILE 'STNGUIDE' ENTERED AT 16:20:33 ON 13 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Nov 9, 2007 (20071109/UP).

=> d l16 1-49 ti

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L16 ANSWER 1 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Compositions comprising inhibitors of inosine-5'-monophosphate dehydrogenase (IMPDH) and an antitumor agent, and use in the treatment of cancer

L16 ANSWER 2 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of quinazolinone derivatives as inosine 5'-monophosphate dehydrogenase inhibitors with therapeutic uses

L16 ANSWER 3 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of quinazolinones as inosine 5'-monophosphate dehydrogenase (IMPDH) inhibitors.

L16 ANSWER 4 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Therapeutic inhibition of protein kinases and a cellular ATP synthetic pathway in cancer cells

L16 ANSWER 5 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Inosine monophosphate dehydrogenase inhibitors and prodrugs in the treatment of cancer and immune disease

L16 ANSWER 6 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of 2-substituted 5-oxazolyl indoles as IMPDH inhibitors, and pharmaceutical compositions comprising same

L16 ANSWER 7 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of sulfonamides as potent inhibitors of IMPDH

L16 ANSWER 8 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of quinazolinone derivatives as inosine 5'-monophosphate dehydrogenase (IMPDH) inhibitors for use in pharmaceutical compositions

L16 ANSWER 9 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of phenylguanidine derivatives as inhibitors of inosine 5'-monophosphate dehydrogenase

L16 ANSWER 10 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
TI 2-Aminoquinolone derivatives for use as IMPDH inhibitors

L16 ANSWER 11 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Preparation of heterocyclic compounds as inhibitors of inosine-5'-monophosphate dehydrogenase (IMPDH)

L16 ANSWER 12 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Preparation of substituted oxazoles as IMPDH inhibitors

L16 ANSWER 13 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Toxicity and efficacy of benzamide riboside in cancer chemotherapy models

L16 ANSWER 14 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Metabolism of the novel IMP dehydrogenase inhibitor benzamide riboside

L16 ANSWER 15 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Potential mechanisms of benzamide riboside mediated cell death

L16 ANSWER 16 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Modulation of cytotoxicity of benzamide riboside by expression of NMN adenylyltransferase

L16 ANSWER 17 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Studies on the mechanism of action of benzamide riboside: a novel inhibitor of IMP dehydrogenase

L16 ANSWER 18 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI The chemistry of nicotinamide adenine dinucleotide (NAD) analogues containing C-nucleosides related to nicotinamide riboside

L16 ANSWER 19 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Mechanism of action of the antitumor agents 6-benzoyl-3,3-disubstituted-1,5-diazabicyclo[3.1.0]hexane-2,4-diones: potent inhibitors of human type II inosine 5'-monophosphate dehydrogenase

L16 ANSWER 20 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Preparation of azolylphenyl oxamides as inosine monophosphate dehydrogenase (IMPDH) inhibitors

L16 ANSWER 21 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Effects of N-substituted phthalimide, saccharin, succinimide, and indandione derivatives on the type I and II isoforms of human Tmol4 T cell IMP dehydrogenase

L16 ANSWER 22 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI In vitro effects of mycophenolic acid on the nucleotide pool and on the expression of adhesion molecules of human umbilical vein endothelial cells

L16 ANSWER 23 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Induction of Tmol4 leukemia cell death by 3,3-disubstituted-6,6-pentamethylene-1,5-diazabicyclo[3.1.0]hexane-2,4-diones: specificity for type II inosine 5'-monophosphate dehydrogenase

L16 ANSWER 24 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Inhibitors of inosine monophosphate dehydrogenase as potential chemotherapeutic agents

L16 ANSWER 25 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Implications of selective type II IMP dehydrogenase (IMPDH) inhibition by the 6-ethoxycarbonyl-3,3-disubstituted-1,5-diazabicyclo[3.1.0]hexane-2,4-diones on tumor cell death

L16 ANSWER 26 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Cofactor analogs as IMPDH inhibitors: Design and new

synthetic approaches.

- L16 ANSWER 27 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Benzamide riboside, a recent inhibitor of IMP dehydrogenase.
- L16 ANSWER 28 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
TI IMPDH and GTP: Linkage with Neoplasia, Target of Chemotherapy, Down Regulation of ras and Signal Transduction.
- L16 ANSWER 29 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Differential sensitivity of ovarian carcinoma cell lines to apoptosis induced by the IMPDH inhibitor benzamide riboside
- L16 ANSWER 30 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Selective Inhibition of Human Molt-4 Leukemia Type II Inosine 5'-Monophosphate Dehydrogenase by the 1,5-Diazabicyclo[3.1.0]hexane-2,4-diones
- L16 ANSWER 31 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Molecular targets of guanine nucleotides in differentiation, proliferation and apoptosis
- L16 ANSWER 32 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Benzamide riboside induces apoptosis independent of Cdc25A expression in human ovarian carcinoma N.1 cells
- L16 ANSWER 33 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Mechanism-based design of inosine 5'-monophosphate dehydrogenase inhibitors: synthesis and biological activities of 5-ethynyl-1- β -D-ribofuranosylimidazole-4-carboxamide (EICAR) and its derivatives
- L16 ANSWER 34 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Nucleoside and non-nucleoside IMP dehydrogenase inhibitors as antitumor and antiviral agents
- L16 ANSWER 35 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Consequences of IMP dehydrogenase inhibition, and its relationship to cancer and apoptosis
- L16 ANSWER 36 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
TI IMP dehydrogenase: structural aspects of inhibitor binding
- L16 ANSWER 37 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Inhibitors of inosine monophosphate dehydrogenase as potential chemotherapeutic agents
- L16 ANSWER 38 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of heterocyclic compounds as inhibitors of inosine-5'-monophosphate dehydrogenase (IMPDH)
- L16 ANSWER 39 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Mycophenolate mofetil reduces production of interferon-dependent major histocompatibility complex induction during allograft rejection, probably by limiting clonal expansion
- L16 ANSWER 40 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Biochemical consequences of resistance to a recently discovered IMP dehydrogenase inhibitor, benzamide riboside, in human myelogenous leukemia K562 cells
- L16 ANSWER 41 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Pyrazole-related nucleosides. Design, synthesis and antiproliferative activity of methyl 4-iodo-1- β -D-ribofuranosyl-pyrazole-3-carboxylate (IPCAR), and derivatives, against human leukemias, lymphomas and solid

tumors cell lines in vitro

- L16 ANSWER 42 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
TI NAD-analogs as potential anticancer agents: Conformational restrictions as basis for selectivity
- L16 ANSWER 43 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Regulation and role of inosine-5'-monophosphate dehydrogenase in cell replication, malignant transformation, and differentiation
- L16 ANSWER 44 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Comparison of biochemical parameters of benzamide riboside, a new inhibitor of IMP dehydrogenase, with tiazofurin and selenazofurin
- L16 ANSWER 45 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Anti-tumor activity of mycophenolate mofetil against human and mouse tumors in vivo
- L16 ANSWER 46 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
TI The search for inosine 5'-phosphate dehydrogenase (IMPDH) inhibitors from marine sponges. Evaluation of the bastadin alkaloids
- L16 ANSWER 47 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Cytotoxicity and characterization of an active metabolite of benzamide riboside, a novel inhibitor of IMP dehydrogenase
- L16 ANSWER 48 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Cytotoxicity of a new IMP dehydrogenase inhibitor, benzamide riboside, to human myelogenous leukemia K562 cells
- L16 ANSWER 49 OF 49 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Cell differentiation and altered IMP dehydrogenase expression induced in human T-lymphoblastoid leukemia cells by mycophenolic acid and tiazofurin

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.30

106.45

FILE 'HCAPLUS' ENTERED AT 16:23:33 ON 13 NOV 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Nov 2007 VOL 147 ISS 21

FILE LAST UPDATED: 12 Nov 2007 (20071112/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s induc?(3a)interferon

2283363 INDUC?
79949 INTERFERON
L20 17277 INDUC?(3A)INTERFERON

=> s l15 and l9

L21 594 L15 AND L9

=> s l15 and l8

L22 0 L15 AND L8

=> s l16 and (PY<2003 or AY<2003 or PRY<2003)

22908320 PY<2003
4466789 AY<2003
3945652 PRY<2003
L23 49 L16 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> s l17 and (PY<2003 or AY<2003 or PRY<2003)

22908320 PY<2003
4466789 AY<2003
3945652 PRY<2003
L24 23 L17 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	2.60	109.05

FILE 'STNGUIDE' ENTERED AT 16:23:43 ON 13 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Nov 9, 2007 (20071109/UP).

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.12	109.17

FILE 'HCAPLUS' ENTERED AT 16:24:53 ON 13 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Nov 2007 VOL 147 ISS 21

FILE LAST UPDATED: 12 Nov 2007 (20071112/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l20 and l9

L25 4720 L20 AND L9

=> s l20 and l8

L26 59 L20 AND L8

=> s l25 and (PY<2003 or AY<2003 or PRY<2003)

22908320 PY<2003

4466789 AY<2003

3945652 PRY<2003

L27 2959 L25 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> s l26 and (PY<2003 or AY<2003 or PRY<2003)

22908320 PY<2003

4466789 AY<2003

3945652 PRY<2003

L28 6 L26 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> file stnguide

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

2.60

111.77

FILE 'STNGUIDE' ENTERED AT 16:25:03 ON 13 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Nov 9, 2007 (20071109/UP).

=> d l28 1-6 ti

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L28 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Vaccine vectors encoding TLR ligand or defensin domain, antigen domain, and antibody domain for modulating dendritic cell and treating cancer, allergy, autoimmune disease, infection and inflammation

L28 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Orthopoxvirus A46R protein modulating IL1R/TLR superfamily signaling and uses in treating NFkB or MAP kinase related diseases

L28 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Methods for stimulating Toll-like receptor TLR to activate IRF3 pathways for inducing anti-microbial, anti-inflammatory and anticancer responses

L28 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Methods for treating cancer

L28 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Adventitial Toll-like receptor ligands for interfering with the formation
 of neointima/scar and/or plaque in a blood vessel

L28 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Toll-like receptor expression reveals CpG DNA as a unique microbial
 stimulus for plasmacytoid dendritic cells which synergizes with CD40
 ligand to induce high amounts of IL-12

=> d l28 1-6 ti abs bib

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L28 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Vaccine vectors encoding TLR ligand or defensin
 domain, antigen domain, and antibody domain for modulating dendritic cell
 and treating cancer, allergy, autoimmune disease, infection and
 inflammation

AB Methods are provided to reduce inflammation and to treat abnormal physiol.
 conditions or diseases by modulating a robust, type 1 adaptive immune
 response in vivo. The present invention also provides proteins and the
 nucleotides encoding them, compns., vectors (including vaccine vectors)
 and delivery vehicles, cells capable of expressing the proteins, and kits
 for practicing the invention. The proteins and nucleotides encode a
 chimeric protein having mol. weight of 100 kDa comprising (1) a TLR
 ligand domain containing a defensin domain, and (2) an antigen domain
 or an antibody domain. The antigen domain is from a self antigen, tumor
 antigen, microorganism antigen, etc. The chimeric proteins or vaccine
 vectors are useful as adjuvant for augmenting cellular or humoral immune
 response against cancer, allergy, asthma, autoimmune disease, infection
 and inflammation.

AN 2004:371070 HCAPLUS <<LOGINID::20071113>>
 DN 140:390286
 TI Vaccine vectors encoding TLR ligand or defensin
 domain, antigen domain, and antibody domain for modulating dendritic cell
 and treating cancer, allergy, autoimmune disease, infection and
 inflammation

IN Biragyn, Arya; Kwak, Larry W.
 PA The United States of America, as Represented by the Secretary Department
 of Health and Human Services, USA
 SO PCT Int. Appl., 98 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004038002	A2	20040506	WO 2003-US33940	20031024 <--
	WO 2004038002	A3	20050127		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2003286692	A1	20040513	AU 2003-286692	20031024 <--
PRAI	US 2002-421488P	P	20021025	<--	
	WO 2003-US33940	W	20031024		

L28 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Orthopoxvirus A46R protein modulating IL1R/TLR superfamily signaling and uses in treating NFkB or MAP kinase related diseases

AB An orthopoxvirus vector, such as vaccinia, is described in which the A46R protein from vaccinia, or a closely related protein from any orthopoxvirus is not expressed or is expressed but is non-functional. Also described is the use of a vaccinia virus A46R protein or a closely related protein from any orthopoxvirus, or a functional peptide, peptidomimetic, fragment or derivative thereof, or a DNA vector expressing any of the above in the modulation and/or inhibition of IL1R/TLR superfamily signaling. A46R inhibited multiple signals induced by the IL-1R/TLR superfamily, including TLR-induced NFkB activation. A46R associated with MyD88 and Mal and blocked signals induced by MyD88 and Mal overexpression. A46R blocked Myd88-independent pathway by associating with TRIF. TLR-4 induced ISRE (interferon-stimulated response element) or IRF3, which are also dependent on TRIF, were also potentially inhibited by A46R. TLR ligand induced ISRE induction in murine macrophages by LPS, and other TLR agonists, was also sensitive to A46R inhibition.

AN 2004:311028 HCAPLUS <<LOGINID::20071113>>

DN 140:337941

TI Orthopoxvirus A46R protein modulating IL1R/TLR superfamily signaling and uses in treating NFkB or MAP kinase related diseases

IN O'Neill, Luke Anthony John; Bowie, Andrew Graham; Stack, Julianne; Smith, Geoffrey Lilley; Haga, Ismar Rocha

PA The Provost, Fellows and Scholars of the College of the Holy and Unidivided Trinity of Queen Elizabeth, Ire.

SO PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004031225	A1	20040415	WO 2003-IE131	20030929 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2499871	A1	20040415	CA 2003-2499871	20030929 <--
	AU 2003273512	A1	20040423	AU 2003-273512	20030929 <--
	EP 1546192	A1	20050629	EP 2003-755669	20030929 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	NZ 539083	A	20070629	NZ 2003-539083	20030929 <--
	US 2005163805	A1	20050728	US 2005-90057	20050328 <--
PRAI	IE 2002-790	A	20021001	<--	
	WO 2003-IE131	W	20030929		

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Methods for stimulating Toll-like receptor TLR to activate IRF3 pathways for inducing anti-microbial, anti-inflammatory and anticancer responses

AB The present invention provides methods for stimulating Toll-like receptors (TLR) to activate IRF (e.g., an IRF3) and signaling pathway, and thereby directing an antimicrobial activity. The present invention also provides methods for identifying agents that bind and/or stimulate TLR and mediate

induction of an IRF3 pathway, thereby directing an antimicrobial activity. Addnl., the invention provides methods and agents for suppressing stimulation of TLR, thereby directing an anti-inflammatory response. IRF3 and NF-KB are involved in TLR3/TLR4-mediated gene activation. NF-KB is required for activation of primary response genes. TLR3/TLR4 stimulation induces production of IFN β and activates antiviral responses. TLR3 is a more potent inducer of antiviral gene expression than TLR4. MyD88, but not TIRAP/mal, directly interacts with TLR3. The TIRAP/mal inhibitory peptide is able to block TLR4 but not TLR3 transactivation of IFN- β and IL-6, as well as IFN- β mediated activation of STAT1. Both TLR3 and TLR4 ligands can induce expression of TLR3 through IFN- β . TLR3 and TLR4 induce both IFN- β -enhanced and IFN- β -dependent antiviral genes. TLR3/4 activation leads to an IFN-dependent G1/S block in murine macrophage cells.

AN 2003:875068 HCAPLUS <<LOGINID::20071113>>

DN 139:358728

TI Methods for stimulating Toll-like receptor TLR to activate IRF3 pathways for inducing anti-microbial, anti-inflammatory and anticancer responses

IN Cheng, Genhong; Modlin, Robert L.; Vaidya, Sagar; Doyle, Sean

PA The Regents of the University of California, USA

SO PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003090685	A2	20031106	WO 2003-US12751	20030424 <--
	WO 2003090685	A3	20040325		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2003243161	A1	20031110	AU 2003-243161	20030424 <--
	US 2006057104	A1	20060316	US 2005-512124	20050826 <--
PRAI	US 2002-375489P	P	20020424 <--		
	WO 2003-US12751	W	20030424		

L28 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Methods for treating cancer

AB Dendritic cells (DC) play a critical role in antigen-specific immune responses. The authors disclose materials and methods for treating disease states, including cancer, by activating dendritic cells from the host which are rendered hypo-responsive to activation stimuli by the disease. In particular, methods are provided for treating cancer in a mammal comprising administering to said mammal an effective amount of a tumor-derived DC inhibitory factor antagonist (e.g., anti-interleukin-10 receptor) in combination with an effective amount of a Toll-like receptor (TLR) agonist.

AN 2003:434399 HCAPLUS <<LOGINID::20071113>>

DN 139:21040

TI Methods for treating cancer

IN Vicari, Alain P.; Caux, Christophe

PA Schering Corporation, USA

SO PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2003045431	A2	20030605	WO 2002-US38098	20021126 <--	
	WO 2003045431	A3	20040122			
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM		
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	CA 2468320	A1	20030605	CA 2002-2468320	20021126 <--	
	AU 2002359516	A1	20030610	AU 2002-359516	20021126 <--	
	US 2003138413	A1	20030724	US 2002-304616	20021126 <--	
	EP 1450858	A2	20040901	EP 2002-794058	20021126 <--	
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK		
	CN 1617742	A	20050518	CN 2002-827598	20021126 <--	
	JP 2006502080	T	20060119	JP 2003-546932	20021126 <--	
	BR 2002014457	A	20061121	BR 2002-14457	20021126 <--	
	MX 2004PA04998	A	20050408	MX 2004-PA4998	20040526 <--	
	ZA 2004004113	A	20060329	ZA 2004-4113	20040526 <--	
	NO 2004002697	A	20040625	NO 2004-2697	20040625 <--	
	JP 2006131638	A	20060525	JP 2005-334633	20051118 <--	
	AU 2006200116	A1	20060202	AU 2006-200116	20060112 <--	
PRAI	US 2001-333434P	P	20011127	<--		
	AU 2002-359516	A3	20021126	<--		
	JP 2003-546932	A3	20021126	<--		
	WO 2002-US38098	W	20021126	<--		

L28 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Adventitial Toll-like receptor ligands for interfering with the formation of neointima/scar and/or plaque in a blood vessel

AB The invention provides a method for interfering with the formation of neointima/scar and/or plaque in a blood vessel comprising providing a ligand capable of modulating Toll-like receptor activity of adventitial cells.

AN 2003:297610 HCAPLUS <<LOGINID::20071113>>

DN 138:297655

TI Adventitial Toll-like receptor ligands for interfering with the formation of neointima/scar and/or plaque in a blood vessel

IN De Kleijn, Dominicus Paschalis Victor; Pasterkamp, Gerard

PA Universitair Medisch Centrum Utrecht, Neth.; Universiteit Utrecht

SO Eur. Pat. Appl., 23 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1302206	A1	20030416	EP 2001-203846	20011011 <--
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR	
	WO 2003030885	A2	20030417	WO 2002-NL644	20021010 <--
	WO 2003030885	A3	20031218		
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002329117 A1 20030422 AU 2002-329117 20021010 <--
PRAI EP 2001-203846 A 20011011 <--
WO 2002-NL644 W 20021010 <--
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Toll-like receptor expression reveals CpG DNA as a unique microbial
stimulus for plasmacytoid dendritic cells which synergizes with CD40
ligand to induce high amounts of IL-12
AB Human plasmacytoid dendritic cells (DC) (PDC, CD123+) and myeloid DC (MDC,
CD11c+) may be able to discriminate between distinct classes of microbial
mols. based on a different pattern of Toll-like receptor (TLR) expression.
TLR1-TLR9 were examined in purified PDC and MDC. TLR9, which is critically
involved in the recognition of CpG motifs in mice, was present in PDC but
not in MDC. TLR4, which is required for the response to LPS, was
selectively expressed on MDC. Consistent with TLR expression, PDC were
susceptible to stimulation by CpG oligodeoxynucleotide (ODN) but not by
LPS, while MDC responded to LPS but not to CpG ODN. In PDC, CpG ODN
supported survival, activation (CD80, CD86, CD40, MHC class II), chemokine
production (IL-8, IP-10) and maturation (CD83). CD40 ligand (CD40L) and CpG
ODN synergized to activate PDC and to stimulate the production of IFN- α
and IL-12 including bioactive IL-12 p70. Previous incubation of PDC with
IL-3 decreased the amount of CpG-induced IFN- α and shifted the
cytokine response in favor of IL-12. CpG ODN-activated PDC showed an
increased ability to stimulate proliferation of naive allogeneic CD4 T
cells, but Th1 polarization of developing T cells required simultaneous
activation of PDC by CD40 ligation and CpG ODN. CpG ODN-stimulated PDC
expressed CCR7, which mediates homing to lymph nodes. In conclusion, the
authors' studies reveal that IL-12 p70 production by PDC is under strict
control of two signals, an adequate exogenous microbial stimulus such as
CpG ODN, and CD40L provided endogenously by activated T cells. Thus, CpG
ODN acts as an enhancer of T cell help, while T cell-controlled
restriction to foreign antigens is maintained.

AN 2001:790371 HCAPLUS <<LOGINID::20071113>>
DN 136:68368
TI Toll-like receptor expression reveals CpG DNA as a unique microbial
stimulus for plasmacytoid dendritic cells which synergizes with CD40
ligand to induce high amounts of IL-12
AU Krug, Anne; Towarowski, Andreas; Britsch, Stefanie; Rothenfusser, Simon;
Hornung, Veit; Bals, Robert; Giese, Thomas; Engelmann, Hartmut; Endres,
Stefan; Krieg, Arthur M.; Hartmann, Gunther
CS Department of Internal Medicine and Division of Clinical Pharmacology,
University of Munich, Munich, Germany
SO European Journal of Immunology (2001), 31(10), 3026-3037
CODEN: EJIMAF; ISSN: 0014-2980
PB Wiley-VCH Verlag GmbH
DT Journal
LA English

RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 16:13:06 ON 13 NOV 2007)

FILE 'REGISTRY' ENTERED AT 16:13:23 ON 13 NOV 2007
EXP MIZORIBINE/CN

L1 1 S E3

L2 0 S MYCOPHENOL/CN
 EXP MYCOPHENOL/CN
 EXP MYCOPHENOLATE SODIUM/CN
 L3 11 S E1-E12
 EXP MYCOPHENOLIC ACID METHYL ESTER/CN
 EXP TIAZOFURIN/CN
 L4 1 S E3
 L5 1 S RIBAVIRIN/CN

FILE 'STNGUIDE' ENTERED AT 16:15:43 ON 13 NOV 2007

FILE 'HCAPLUS' ENTERED AT 16:18:59 ON 13 NOV 2007

L6 7877 S L1 OR L3-L5
 L7 263 S (IMPDH OR (INOSINE MONOPHOSPHAE DEHYDROGENASE)) (2A) INHIBIT?
 L8 607 S (INDUC(3A)INTERFERON) OR (CPG NUCLEOTIDE) OR ((TLR OR (TOLL-L
 L9 790563 S CANCER OR TUMOR OR NEOPLAS?
 L10 1002 S L6 AND L9
 L11 70 S L7 AND L9
 L12 267 S L8 AND L9
 L13 2 S (L6 OR L7) AND L8
 L14 2 S L13 AND L9

FILE 'STNGUIDE' ENTERED AT 16:19:11 ON 13 NOV 2007

FILE 'HCAPLUS' ENTERED AT 16:20:15 ON 13 NOV 2007

L15 594 S L10 AND (PY<2003 OR AY<2003 OR PRY<2003)
 L16 49 S L11 AND (PY<2003 OR AY<2003 OR PRY<2003)
 L17 23 S L12 AND (PY<2003 OR AY<2003 OR PRY<2003)
 L18 0 S L13 AND (PY<2003 OR AY<2003 OR PRY<2003)
 L19 0 S L14 AND (PY<2003 OR AY<2003 OR PRY<2003)

FILE 'STNGUIDE' ENTERED AT 16:20:33 ON 13 NOV 2007

FILE 'HCAPLUS' ENTERED AT 16:20:46 ON 13 NOV 2007

FILE 'STNGUIDE' ENTERED AT 16:20:47 ON 13 NOV 2007

FILE 'HCAPLUS' ENTERED AT 16:23:33 ON 13 NOV 2007

L20 17277 S INDUC?(3A)INTERFERON
 L21 594 S L15 AND L9
 L22 0 S L15 AND L8
 L23 49 S L16 AND (PY<2003 OR AY<2003 OR PRY<2003)
 L24 23 S L17 AND (PY<2003 OR AY<2003 OR PRY<2003)

FILE 'STNGUIDE' ENTERED AT 16:23:43 ON 13 NOV 2007

FILE 'HCAPLUS' ENTERED AT 16:24:53 ON 13 NOV 2007

L25 4720 S L20 AND L9
 L26 59 S L20 AND L8
 L27 2959 S L25 AND (PY<2003 OR AY<2003 OR PRY<2003)
 L28 6 S L26 AND (PY<2003 OR AY<2003 OR PRY<2003)

FILE 'STNGUIDE' ENTERED AT 16:25:03 ON 13 NOV 2007

FILE 'HCAPLUS' ENTERED AT 16:25:15 ON 13 NOV 2007

FILE 'STNGUIDE' ENTERED AT 16:25:15 ON 13 NOV 2007

FILE 'HCAPLUS' ENTERED AT 16:25:52 ON 13 NOV 2007

FILE 'STNGUIDE' ENTERED AT 16:25:52 ON 13 NOV 2007

=> log hold

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST	ENTRY 0.06	SESSION 136.17
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-4.68

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 16:26:07 ON 13 NOV 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'STNGUIDE' AT 16:28:11 ON 13 NOV 2007
FILE 'STNGUIDE' ENTERED AT 16:28:11 ON 13 NOV 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	136.17

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-4.68

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.12	136.23

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-4.68

FILE 'HCAPLUS' ENTERED AT 16:28:38 ON 13 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Nov 2007 VOL 147 ISS 21
FILE LAST UPDATED: 12 Nov 2007 (20071112/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate

substance identification.

=> s 120 and 17

L29 2 L20 AND L7

=> s 129 and (PY<2003 or AY<2003 or PRY<2003)

22908320 PY<2003

4466789 AY<2003

3945652 PRY<2003

L30 0 L29 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	2.60	138.83
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-4.68

FILE 'STNGUIDE' ENTERED AT 16:28:42 ON 13 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Nov 9, 2007 (20071109/UP).

=> d 129 1-2 ti abs bib

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L29 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Genes showing altered expression in response to inhibition of
inosine-5'-monophosphate dehydrogenase and their use in monitoring
response to drugs
AB Genes that show altered levels of expression in response to inhibitors of
inosine-5'-monophosphate dehydrogenase (IMPDH) are identified. These
genes may be useful as markers in the study of the response of an
individual to treatment, e.g. of infection or cancer, by IMPDH inhibitors
such as mycophenolic acid or VX-944.
AN 2005:1314010 HCAPLUS <<LOGINID::20071113>>
DN 144:64332
TI Genes showing altered expression in response to inhibition of
inosine-5'-monophosphate dehydrogenase and their use in monitoring
response to drugs
IN Jain-Pandey, Jugnu; Harding, Matthew W.; Ramachandran, Ravi; Botfield,
Martyn; Kelliher, Kevin; Shames, Benjamin
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 543 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005117943	A2	20051215	WO 2005-US18551	20050527
	WO 2005117943	A3	20061019		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,			

LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

AU 2005249446 A1 20051215 AU 2005-249446 20050527
CA 2568405 A1 20051215 CA 2005-2568405 20050527
EP 1766091 A2 20070328 EP 2005-804844 20050527

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA,
HR, LV, MK, YU

CN 101023185 A 20070822 CN 2005-80025460 20050527
IN 2006DN07940 A 20070427 IN 2006-DN7940 20061227

PRAI US 2004-575076P P 20040527
WO 2005-US18551 W 20050527

L29 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Combined use of inosine monophosphate dehydrogenase (IMPDH)
inhibitors with toll-like receptor agonists for immune system
activation and treatment of diseases

AB The present invention provides a broad-spectrum, long-lasting, and
non-toxic combination of synthetic immunostimulatory agents, which are
useful for activating the immune system of a mammal and treating diseases
such as cancer and autoimmune disease. These agents include TLR-ligands
and ligand analogs which induce interferon production, in
combination with inhibitors of inosine monophosphate dehydrogenase
(IMPDH), that further enhance the induction of
interferon production In mice that were injected with 250 µg of
7-thia-8-oxoguanosine (TLR-7 ligand), addition of mizoribine (IMPDH
inhibitor) increased levels of Type I interferon in blood more
than 4-fold.

AN 2005:15938 HCAPLUS <<LOGINID::20071113>>

DN 142:107390

TI Combined use of inosine monophosphate dehydrogenase (IMPDH)
inhibitors with toll-like receptor agonists for immune system
activation and treatment of diseases

IN Carson, Dennis A.; Cottam, Howard B.; Lee, Jongdae

PA Regents of the University of California, USA

SO U.S. Pat. Appl. Publ., 59 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005004144	A1	20050106	US 2004-824833	20040414
	WO 2005016235	A2	20050224	WO 2004-US11566	20040414
	WO 2005016235	A3	20060316		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG

PRAI US 2003-463152P P 20030414

OS MARPAT 142:107390

=> log ohld
'OHL'D' IS NOT VALID HERE
For an explanation, enter "HELP LOGOFF".

=> log hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	147.21
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-6.24

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 16:29:01 ON 13 NOV 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'STNGUIDE' AT 16:59:08 ON 13 NOV 2007
FILE 'STNGUIDE' ENTERED AT 16:59:08 ON 13 NOV 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	147.21
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-6.24

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.12	147.27
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-6.24

FILE 'HCAPLUS' ENTERED AT 17:00:10 ON 13 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing

of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Nov 2007 VOL 147 ISS 21
FILE LAST UPDATED: 12 Nov 2007 (20071112/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s ((inosine monophosphate dehydrogenase)or(IMPDH)) and interferon and (cancer or tumor or neoplas?)

11564 INOSINE
32358 MONOPHOSPHATE
171702 DEHYDROGENASE
629 INOSINE MONOPHOSPHATE DEHYDROGENASE
(INOSINE(W)MONOPHOSPHATE(W)DEHYDROGENASE)
470 IMPDH
79949 INTERFERON
336770 CANCER
428563 TUMOR
517459 NEOPLAS?

L31 21 ((INOSINE MONOPHOSPHATE DEHYDROGENASE)OR(IMPDH)) AND INTERFERON
AND (CANCER OR TUMOR OR NEOPLAS?)

=> sile stnguide

SILE IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d l31 1-21 ti

L31 ANSWER 1 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon- α

L31 ANSWER 2 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Gene expression profiling in peripheral blood mononuclear cells in the diagnosis and therapy of vascular disease

L31 ANSWER 3 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Gene expression profiles in multiple brain structures in the diagnosis and therapy of neuropsychiatric disorders

L31 ANSWER 4 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Immunosuppression using the mTOR inhibition mechanism affects replacement of rat liver with transplanted cells

L31 ANSWER 5 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Methods using agents that increase the level of a Type I interferon and/or activate a Type I interferon signaling pathway for treating gastrointestinal inflammation

L31 ANSWER 6 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN
TI New therapies and emerging strategies to combat infection with the hepatitis C virus

L31 ANSWER 7 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Gene expression profiles in peripheral blood mononuclear cells in determination of the nature and severity of stroke

L31 ANSWER 8 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Diagnosis of pulmonary arterial hypertension and monitoring of therapy using gene expression analysis of peripheral blood cells

L31 ANSWER 9 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Genes showing altered levels of expression in drug-resistant leukemia and their use in diagnosis and selection of drug target for therapy

L31 ANSWER 10 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Genes showing altered expression in response to inhibition of inosine-5'-monophosphate dehydrogenase and their use in monitoring response to drugs

L31 ANSWER 11 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Differential expression of molecules associated with acute stroke

L31 ANSWER 12 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Antimetabolite antiviral dosing regimen for hepatitis C virus or flaviviridae therapy

L31 ANSWER 13 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Combined use of inosine monophosphate dehydrogenase (IMPDH) inhibitors with toll-like receptor agonists for immune system activation and treatment of diseases

L31 ANSWER 14 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Viramidine hydrochloride

L31 ANSWER 15 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Method for treating diseases with omega interferon

L31 ANSWER 16 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI The mosaic of immunosuppressive drugs

L31 ANSWER 17 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Protein-protein interaction domains of adipocyte proteins and method for screening for association-inhibiting drugs

L31 ANSWER 18 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Identification of an IMPDH1 mutation in autosomal dominant retinitis pigmentosa (RP10) revealed following comparative microarray analysis of transcripts derived from retinas of wild-type and Rho-/- mice

L31 ANSWER 19 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Detection of variations in the DNA methylation profile of genes in the determining the risk of disease

L31 ANSWER 20 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Apoptosis of superantigen-activated T cells induced by mycophenolate mofetil treatment

L31 ANSWER 21 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Mycophenolate mofetil reduces production of interferon-dependent major histocompatibility complex induction during allograft rejection, probably by limiting clonal expansion

=> file stnguide

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

9.74

157.01

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-6.24

FILE 'STNGUIDE' ENTERED AT 17:00:26 ON 13 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Nov 9, 2007 (20071109/UP).

=> d l31 file hcaplus
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:s l31 and (PY<2004 or
AY<2004 or PRY<2004)

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:file stnguide

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:n

=> file hcaplus

	SINCE FILE	TOTAL
	ENTRY	SESSION
COST IN U.S. DOLLARS		
FULL ESTIMATED COST	0.12	157.13
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-6.24

FILE 'HCAPLUS' ENTERED AT 17:01:36 ON 13 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Nov 2007 VOL 147 ISS 21
FILE LAST UPDATED: 12 Nov 2007 (20071112/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l31 and (PY<2004 or AY<2004 or PRY<2004)

23955873 PY<2004
4750146 AY<2004
4232403 PRY<2004

L32 9 L31 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> file stnguide

	SINCE FILE	TOTAL
	ENTRY	SESSION

FULL ESTIMATED COST	2.60	159.73
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-6.24

FILE 'STNGUIDE' ENTERED AT 17:01:40 ON 13 NOV 2007
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
 LAST RELOADED: Nov 9, 2007 (20071109/UP).

=> d l31 1-9 ti
 YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L31 ANSWER 1 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon- α

L31 ANSWER 2 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Gene expression profiling in peripheral blood mononuclear cells in the diagnosis and therapy of vascular disease

L31 ANSWER 3 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Gene expression profiles in multiple brain structures in the diagnosis and therapy of neuropsychiatric disorders

L31 ANSWER 4 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Immunosuppression using the mTOR inhibition mechanism affects replacement of rat liver with transplanted cells

L31 ANSWER 5 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Methods using agents that increase the level of a Type I interferon and/or activate a Type I interferon signaling pathway for treating gastrointestinal inflammation

L31 ANSWER 6 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI New therapies and emerging strategies to combat infection with the hepatitis C virus

L31 ANSWER 7 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Gene expression profiles in peripheral blood mononuclear cells in determination of the nature and severity of stroke

L31 ANSWER 8 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Diagnosis of pulmonary arterial hypertension and monitoring of therapy using gene expression analysis of peripheral blood cells

L31 ANSWER 9 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Genes showing altered levels of expression in drug-resistant leukemia and their use in diagnosis and selection of drug target for therapy

=> d l31 1 2 5 6 7 ti abs bib
 YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L31 ANSWER 1 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon- α

AB Background & Aims: Chronic hepatitis C virus (HCV) infection is the leading indication for liver transplantation. Clin. evidence suggests that particular immunosuppressive agents can have an influence on HCV recurrence. Cyclosporine A (CsA) specifically inhibits HCV replication through blocking the viral RNA polymerase enzyme NS5B. In this study, we investigated the effect of mycophenolic acid (MPA) and other immunosuppressants on HCV replication. Methods: MPA and other compds. were tested in vitro using an HCV-replication model containing a luciferase reporter gene. Results: At clin. relevant concns. (1.0-6.0 µg/mL), MPA inhibited HCV replication to approx. 75%. CsA and interferon (IFN)-α also showed inhibition in a dose-dependent manner. In these short-term (18 h) expts., MPA did not inhibit cell proliferation or induce cell death, which could have accounted for the antiviral effect. In contrast to the antiviral activity of MPA against West Nile virus, the effect of MPA on HCV replication was guanosine independent. When combined, MPA and CsA showed significant synergistic inhibition of replication, reaching maximum inhibition of .apprx.90% at the highest doses. Synergistic effects were observed with suboptimal concns. of IFN-α with MPA or CsA. The kinetics of HCV inhibition by MPA, CsA, and IFN-α were clearly distinct, with earliest effects seen with IFN-α. No specific inhibitory effects were observed with tacrolimus or rapamycin. Conclusions: The immunosuppressive drug MPA is as potent as CsA as an inhibitor of HCV replication. MPA was shown to have a distinct anti-HCV mechanism of action, independent of cell proliferation and guanosine depletion.

AN 2006:1324492 HCAPLUS <<LOGINID::20071113>>

DN 146:198108

TI Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-α

AU Henry, Scot D.; Metselaar, Herold J.; Lonsdale, Richard C. B.; Kok, Alice; Haagmans, Bart L.; Tilanus, Hugo W.; Van Der Laan, Luc J. W.

CS Department of Surgery, Erasmus MC-University Medical Center, Rotterdam, Neth.

SO Gastroenterology (2006), 131(5), 1452-1462

CODEN: GASTAB; ISSN: 0016-5085

PB Elsevier Inc.

DT Journal

LA English

RE.CNT 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 2 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Gene expression profiling in peripheral blood mononuclear cells in the diagnosis and therapy of vascular disease

AB Methods of using peripheral blood mononuclear cells to evaluate vascular disease, such as predicting a subject's risk of vascular disease, determining a treatment regimen for a subject who has such as risk, or combinations thereof. These methods involve anal. of gene expression profiles in monocytes to identify changes associated with vascular disease. Methods of using gene expression profile data in screening for drugs for use in the treatment of vascular disease and in the monitoring of the effectiveness of therapy.

AN 2006:1312594 HCAPLUS <<LOGINID::20071113>>

DN 146:60481

TI Gene expression profiling in peripheral blood mononuclear cells in the diagnosis and therapy of vascular disease

IN Baird, Alison E.; Moore, David F.; Goldin, Ehud

PA The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services, USA

SO PCT Int. Appl., 132pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006132983	A2	20061214	WO 2006-US21491	20060602
	WO 2006132983	A3	20070301		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2005-687515P	P	20050603		
	US 2005-691730P	P	20050617		

L31 ANSWER 5 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Methods using agents that increase the level of a Type I interferon and/or activate a Type I interferon signaling pathway for treating gastrointestinal inflammation

AB The invention provides methods for treating gastrointestinal inflammation, methods for treating inflammatory bowel disease, methods for treating Crohn's Disease, and methods for treating ulcerative colitis in an individual. The methods generally involve administering an effective amount of an agent that increases the level of a Type I interferon and/or that activates a Type I interferon signaling pathway in the individual.

AN 2006:884433 HCAPLUS <<LOGINID::20071113>>

DN 145:285155

TI Methods using agents that increase the level of a Type I interferon and/or activate a Type I interferon signaling pathway for treating gastrointestinal inflammation

IN Rachmilewitz, Daniel; Raz, Eyal; Katakura, Kyoko; Lee, Jongdae

PA The Regents of the University of California, USA

SO PCT Int. Appl., 88pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006091591	A1	20060831	WO 2006-US6095	20060221
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2006216822	A1	20060831	AU 2006-216822	20060221
	CA 2598831	A1	20060831	CA 2006-2598831	20060221
	US 2007004654	A1	20070104	US 2006-359945	20060221
PRAI	US 2005-655455P	P	20050222		
	WO 2006-US6095	W	20060221		

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 6 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI New therapies and emerging strategies to combat infection with the hepatitis C virus
 AB A review. Therapy for chronic hepatitis C has advanced rapidly over the last 15 years. Current therapies are able to suppress viral replication, control disease progression, or achieve sustained virus elimination in a proportion of those infected. There are also significant challenges to the clin. management of this infection, which are imposed mainly by the virus capacity to develop resistance to the current antiviral drugs, suboptimal efficacy of these drugs, and the rigors of the treatment regimen. This triggers the need for refined treatment regimens and the search for newer therapeutic agents. The most effective current therapies for the treatment of hepatitis C virus infection are discussed. An update of new drug candidates, particularly those in the latest stages of development, is provided.
 AN 2006:228700 HCAPLUS <<LOGINID::20071113>>
 DN 145:201610
 TI New therapies and emerging strategies to combat infection with the hepatitis C virus
 AU Bean, Pamela
 CS Rogers Memorial Hospital, Madison, WI, USA
 SO American Biotechnology Laboratory (2006), 24(2), 4-6
 CODEN: ABLAEY; ISSN: 0749-3223
 PB International Scientific Communications, Inc.
 DT Journal; General Review
 LA English

L31 ANSWER 7 OF 21 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Gene expression profiles in peripheral blood mononuclear cells in determination of the nature and severity of stroke
 AB A method for rapid and accurate diagnosis of the nature and severity of a stroke by measuring gene expression in peripheral blood mononuclear cells is described. Early diagnosis can be used to predict and prevent possible complications. The genes showing altered levels of expression include those associated with white blood cell activation and differentiation; in response to hypoxia, in vascular repair, and those related to a specific peripheral blood mononuclear cell (PBMC) response to the altered cerebral microenvironment. Also provided are methods of identifying one or more agents that alter the activity (such as the expression) of an ischemic stroke-related mol.
 AN 2006:191859 HCAPLUS <<LOGINID::20071113>>
 DN 144:252185
 TI Gene expression profiles in peripheral blood mononuclear cells in determination of the nature and severity of stroke
 IN Baird, Alison E.; Moore, David F.; Goldin, Ehud
 PA The Gov. Of the U.S.A as Represented by the Secretary of the Dept. Of Health & Human Services, USA
 SO U.S. Pat. Appl. Publ., 67 pp., Cont.-in-part of Appl. No. PCT/US05/018744.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006046259	A1	20060302	US 2005-155835	20050617
	WO 2005116268	A2	20051208	WO 2005-US18744	20050527
	WO 2005116268	A3	20061214		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,				

ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG
 PRAI US 2004-575279P P 20040527
 WO 2005-US18744 A2 20050527

=> d his

(FILE 'HOME' ENTERED AT 16:13:06 ON 13 NOV 2007)

FILE 'REGISTRY' ENTERED AT 16:13:23 ON 13 NOV 2007

EXP MIZORIBINE/CN
 L1 1 S E3
 L2 0 S MYCOPHENOL/CN
 EXP MYCOPHENOL/CN
 EXP MYCOPHENOLATE SODIUM/CN
 L3 11 S E1-E12
 EXP MYCOPHENOLIC ACID METHYL ESTER/CN
 EXP TIAZOFURIN/CN
 L4 1 S E3
 L5 1 S RIBAVIRIN/CN

FILE 'STNGUIDE' ENTERED AT 16:15:43 ON 13 NOV 2007

FILE 'HCAPLUS' ENTERED AT 16:18:59 ON 13 NOV 2007

L6 7877 S L1 OR L3-L5
 L7 263 S (IMPDH OR (INOSINE MONOPHOSPHAE DEHYDROGENASE)) (2A) INHIBIT?
 L8 607 S (INDUC(3A) INTERFERON) OR (CPG NUCLEOTIDE) OR ((TLR OR (TOLL-L
 L9 790563 S CANCER OR TUMOR OR NEOPLAS?
 L10 1002 S L6 AND L9
 L11 70 S L7 AND L9
 L12 267 S L8 AND L9
 L13 2 S (L6 OR L7) AND L8
 L14 2 S L13 AND L9

FILE 'STNGUIDE' ENTERED AT 16:19:11 ON 13 NOV 2007

FILE 'HCAPLUS' ENTERED AT 16:20:15 ON 13 NOV 2007

L15 594 S L10 AND (PY<2003 OR AY<2003 OR PRY<2003)
 L16 49 S L11 AND (PY<2003 OR AY<2003 OR PRY<2003)
 L17 23 S L12 AND (PY<2003 OR AY<2003 OR PRY<2003)
 L18 0 S L13 AND (PY<2003 OR AY<2003 OR PRY<2003)
 L19 0 S L14 AND (PY<2003 OR AY<2003 OR PRY<2003)

FILE 'STNGUIDE' ENTERED AT 16:20:33 ON 13 NOV 2007

FILE 'HCAPLUS' ENTERED AT 16:20:46 ON 13 NOV 2007

FILE 'STNGUIDE' ENTERED AT 16:20:47 ON 13 NOV 2007

FILE 'HCAPLUS' ENTERED AT 16:23:33 ON 13 NOV 2007

L20 17277 S INDUC?(3A) INTERFERON
 L21 594 S L15 AND L9
 L22 0 S L15 AND L8
 L23 49 S L16 AND (PY<2003 OR AY<2003 OR PRY<2003)
 L24 23 S L17 AND (PY<2003 OR AY<2003 OR PRY<2003)

FILE 'STNGUIDE' ENTERED AT 16:23:43 ON 13 NOV 2007

FILE 'HCAPLUS' ENTERED AT 16:24:53 ON 13 NOV 2007

L25 4720 S L20 AND L9
L26 59 S L20 AND L8
L27 2959 S L25 AND (PY<2003 OR AY<2003 OR PRY<2003)
L28 6 S L26 AND (PY<2003 OR AY<2003 OR PRY<2003)

FILE 'STNGUIDE' ENTERED AT 16:25:03 ON 13 NOV 2007

FILE 'HCAPLUS' ENTERED AT 16:25:15 ON 13 NOV 2007

FILE 'STNGUIDE' ENTERED AT 16:25:15 ON 13 NOV 2007

FILE 'HCAPLUS' ENTERED AT 16:25:52 ON 13 NOV 2007

FILE 'STNGUIDE' ENTERED AT 16:25:52 ON 13 NOV 2007

FILE 'HCAPLUS' ENTERED AT 16:28:38 ON 13 NOV 2007

L29 2 S L20 AND L7

L30 0 S L29 AND (PY<2003 OR AY<2003 OR PRY<2003)

FILE 'STNGUIDE' ENTERED AT 16:28:42 ON 13 NOV 2007

FILE 'HCAPLUS' ENTERED AT 16:28:53 ON 13 NOV 2007

FILE 'STNGUIDE' ENTERED AT 16:28:53 ON 13 NOV 2007

FILE 'HCAPLUS' ENTERED AT 17:00:10 ON 13 NOV 2007

L31 21 S ((INOSINE MONOPHOSPHATE DEHYDROGENASE)OR(IMPDH)) AND INTERFER

FILE 'STNGUIDE' ENTERED AT 17:00:26 ON 13 NOV 2007

FILE 'HCAPLUS' ENTERED AT 17:01:36 ON 13 NOV 2007

L32 9 S L31 AND (PY<2004 OR AY<2004 OR PRY<2004)

FILE 'STNGUIDE' ENTERED AT 17:01:40 ON 13 NOV 2007

FILE 'HCAPLUS' ENTERED AT 17:01:45 ON 13 NOV 2007

FILE 'STNGUIDE' ENTERED AT 17:01:46 ON 13 NOV 2007

FILE 'HCAPLUS' ENTERED AT 17:02:35 ON 13 NOV 2007

FILE 'STNGUIDE' ENTERED AT 17:02:36 ON 13 NOV 2007

=> log hold

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.06

182.32

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-10.14

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 17:02:41 ON 13 NOV 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'STNGUIDE' AT 17:03:46 ON 13 NOV 2007
FILE 'STNGUIDE' ENTERED AT 17:03:46 ON 13 NOV 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.06	182.32
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-10.14

=> d l31 1 2 5 6 7 ti abs bib
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:n

=> d l32 1 2 5 6 7 ti abs bib
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L32 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Antimetabolite antiviral dosing regimen for hepatitis C virus or
flaviviridae therapy
AB An anti-hepatitis C agent which is an anti-metabolite to the host and
cannot be administered on a daily or chronic basis as is usual in
anti-viral therapy (referred to below as an "anti-HCV anti-metabolite"),
can be administered using a traditional anti-cancer dosing
regimen (for example via i.v. or parenteral injection), over a period of
1-7 days followed by cessation of therapy until rebound of the viral load
is noted. This dosing regimen runs counter to conventional antiviral
experience, wherein effective agents are usually administered over at
least fourteen days of sustained therapy, and typically on an indefinite
daily basis.
AN 2005:177803 HCAPLUS <<LOGINID::20071113>>
DN 142:254560
TI Antimetabolite antiviral dosing regimen for hepatitis C virus or
flaviviridae therapy
IN Stuyver, Lieven J.
PA Pharmasset, Inc., USA
SO PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005018330	A1	20050303	WO 2004-US26686	20040817 <--
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				
	NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				
	TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,				
	AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				
	EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,				
	SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,				
	SN, TD, TG				

PRAI US 2003-496202P P 20030818 <--
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Combined use of inosine monophosphate dehydrogenase (IMPDH) inhibitors with toll-like receptor agonists for immune system activation and treatment of diseases

AB The present invention provides a broad-spectrum, long-lasting, and non-toxic combination of synthetic immunostimulatory agents, which are useful for activating the immune system of a mammal and treating diseases such as cancer and autoimmune disease. These agents include TLR-ligands and ligand analogs which induce interferon production, in combination with inhibitors of inosine monophosphate dehydrogenase (IMPDH), that further enhance the induction of interferon production. In mice that were injected with 250 µg of 7-thia-8-oxoguanosine (TLR-7 ligand), addition of mizoribine (IMPDH inhibitor) increased levels of Type I interferon in blood more than 4-fold.

AN 2005:15938 HCAPLUS <<LOGINID::20071113>>

DN 142:107390

TI Combined use of inosine monophosphate dehydrogenase (IMPDH) inhibitors with toll-like receptor agonists for immune system activation and treatment of diseases

IN Carson, Dennis A.; Cottam, Howard B.; Lee, Jongdae

PA Regents of the University of California, USA

SO U.S. Pat. Appl. Publ., 59 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005004144	A1	20050106	US 2004-824833	20040414 <--
	WO 2005016235	A2	20050224	WO 2004-US11566	20040414 <--
	WO 2005016235	A3	20060316		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-463152P P 20030414 <--

OS MARPAT 142:107390

L32 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Protein-protein interaction domains of adipocyte proteins and method for screening for association-inhibiting drugs

AB The present invention relates to protein-protein interactions of adipocytes. More specifically, the present invention relates to complexes of polypeptides, or polynucleotides encoding the polypeptides, interaction domains of the polypeptides, methods for screening drugs which modulate the interaction of proteins, and pharmaceutical compns. that are capable of modulating the protein-protein interactions. Thus, gene expression profiles of differentiated and undifferentiated human PAZ6 cells indicated that genes for the following proteins were overexpressed in the differentiated cells (adipocytes): protein TPT1 (tumor protein, translationally controlled, 1), leptin, complement component 1, thymosin β4, fibulin 1C, osteonectin, β2-microglobulin, proteasome subunit p31, huntingtin-interacting protein 2, and two interferon-inducible proteins. In a modified yeast two-hybrid system, the protein interaction domains of these proteins were used as bait to identify

proteins with which they interact. The DVL1, DVL2, and DVL3 (dishevelled 1, 2 and 3) proteins of the Wnt signaling pathway were all found to interact with the PSMD8 protein, i.e., proteasome subunit p31.

AN 2002:869083 HCAPLUS <<LOGINID::20071113>>

DN 137:381501

TI Protein-protein interaction domains of adipocyte proteins and method for screening for association-inhibiting drugs

IN Legrain, Pierre; Whiteside, Simon; Mao, Jen-I.; Khrebtukova, Irina; Luo, Shujun

PA Hybrigenics, Fr.; Lynx Therapeutics, Inc.

SO PCT Int. Appl., 232 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002090544	A2	20021114	WO 2002-EP6333	20020503 <--
	WO 2002090544	A3	20031120		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002341232	A1	20021118	AU 2002-341232	20020503 <--
	US 2003232421	A1	20031218	US 2002-139794	20020506 <--
PRAI	US 2001-288885P	P	20010504	<--	
	WO 2002-EP6333	W	20020503	<--	

L32 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Identification of an IMPDH1 mutation in autosomal dominant retinitis pigmentosa (RP10) revealed following comparative microarray analysis of transcripts derived from retinas of wild-type and Rho-/- mice

AB Comparative anal. of the transcriptional profiles of approx. 6000 genes in the retinas of wild-type mice with those carrying a targeted disruption of the rhodopsin gene was undertaken by microarray anal. This revealed a series of transcripts, of which some were derived from genes known to map at retinopathy loci, levels of which were reduced or elevated in the retinas of Rho-/- mice lacking functional photoreceptors. The human homolog of one of these genes, encoding inosine monophosphate dehydrogenase type 1 (IMPDH1), maps to the region of 7q to which an adRP gene (RP10) had previously been localized. Mutational screening of DNA from the Spanish adRP family, originally used to localize the RP10 gene, revealed an Arg224Pro substitution co-segregating with the disease phenotype. The amino acid at position 224 of the IMPDH1 protein is conserved among species and the substitution is not present in healthy, unrelated individuals of European origin. These data provide strong evidence that mutations within the IMPDH1 gene cause adRP, and validate approaches to mutation detection involving comparative anal. of global transcription profiles in normal and degenerating retinal tissues. Other genes showing significant alterations in expression include some with anti-apoptotic functions and many encoding components of the extracellular matrix or cytoskeleton, a possible reflection of a response by Muller cells to preserve the remaining outer nuclear layer of the retina. We suggest that those genes identified are prime candidates for etiol. involvement in degenerative retinal disease.

AN 2002:231139 HCAPLUS <<LOGINID::20071113>>

DN 137:164502

TI Identification of an IMPDH1 mutation in autosomal dominant retinitis

pigmentosa (RP10) revealed following comparative microarray analysis of transcripts derived from retinas of wild-type and Rho-/- mice

AU Kennan, Avril; Aherne, Aileen; Palfi, Arpad; Humphries, Marian; McKee, Alex; Stitt, Alan; Simpson, David A. C.; Demtroder, Karin; Orntoft, Torben; Ayuso, Carmen; Kenna, Paul F.; Farrar, G. Jane; Humphries, Pete

CS The Ocular Genetics Unit, Department of Genetics, Trinity College, Dublin, 2, Ire.

SO Human Molecular Genetics (2002), 11(5), 547-558
CODEN: HMGEE5; ISSN: 0964-6906

PB Oxford University Press

DT Journal

LA English

RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L32 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Detection of variations in the DNA methylation profile of genes in the determining the risk of disease

AB The invention relates to an oligonucleotide kit as probe for the detection of relevant variations in the DNA methylation of a target group of genes. The invention further relates to the use of the same for determining the gene variant with regard to DNA methylation, a medical device, using an oligonucleotide kit, a method for determining the methylation state of an individual and a method for the establishment of a model for establishing the probability of onset of a disease state in an individual. Such diseases may be: undesired pharmaceutical side-effects; cancerous diseases; CNS dysfunctions, injuries or diseases; aggressive symptoms or relational disturbances; clin., psychol. and social consequences of brain injury; psychotic disorders and personality disorders; dementia and/or associated syndromes; cardiovascular disease, dysfunction and damage; dysfunction, damage or disease of the gastrointestinal tract; dysfunction, damage or disease of the respiratory system; injury, inflammation, infection, immunity and/or anastasis; dysfunction, damage or disease of the body as an abnormal development process; dysfunction, damage or disease of the skin, muscle, connective tissue or bones; endocrine and metabolic dysfunction, damage or disease; headaches or sexual dysfunction. This abstract record is one of several records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.

AN 2001:763235 HCAPLUS <<LOGINID::20071113>>

DN 135:314399

TI Detection of variations in the DNA methylation profile of genes in the determining the risk of disease

IN Berlin, Kurt; Piepenbrock, Christian; Olek, Alexander

PA Epigenomics A.-G., Germany

SO PCT Int. Appl., 636 pp.
CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 69

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001077373	A2	20011018	WO 2001-DE1486	20010406 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 10019058	A1	20011220	DE 2000-10019058	20000406 <--
	WO 2001077373	A2	20011018	WO 2001-XA1486	20010406 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CR, CU, CZ, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
 ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
 LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,
 SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 CF, CG, CI, CM, GA, GW, ML, MR, NE, SN, TD, TG

WO 2001077373 A2 20011018 WO 2001-XB1486 20010406 <--
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CR, CU, CZ, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
 ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
 LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,
 SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 CF, CG, CI, CM, GA, GW, ML, MR, NE, SN, TD, TG

AU 200173840 A 20011023 AU 2001-73840 20010406 <--
 AU 200177487 A 20011023 AU 2001-77487 20010406 <--
 EP 1278892 A1 20030129 EP 2001-940158 20010406 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 EP 1360319 A2 20031112 EP 2001-955278 20010406 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

AT 339520 T 20061015 AT 2002-90203 20020605 <--
 ES 2272636 T3 20070501 ES 2002-2090203 20020605 <--
 US 2004067491 A1 20040408 US 2003-240454 20030311 <--
 AU 2003204553 A1 20040108 AU 2003-204553 20030605 <--
 JP 2004008217 A 20040115 JP 2003-160375 20030605 <--
 US 2004023279 A1 20040205 US 2003-455212 20030605 <--
 US 2007026393 A1 20070201 US 2003-240970 20030711 <--
 AU 2006203475 A1 20060831 AU 2006-203475 20060811 <--
 AU 2006213968 A1 20061019 AU 2006-213968 20060915 <--
 AU 2006225250 A1 20061026 AU 2006-225250 20061005 <--

PRAI DE 2000-10019058 A 20000406 <--
 DE 2000-10019173 A 20000407 <--
 DE 2000-10032529 A 20000630 <--
 DE 2000-10043826 A 20000901 <--
 AU 2001-275663 A 20010406 <--
 AU 2001-276331 A3 20010406 <--
 AU 2001-75663 A 20010406 <--
 WO 2001-DE1486 W 20010406 <--
 WO 2001-EP4016 W 20010406 <--
 EP 2002-90203 A 20020605 <--
 AU 2006-230475 A 20060811

=> log hold

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.06

199.13

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-14.04

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 17:04:00 ON 13 NOV 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'STNGUIDE' AT 17:05:54 ON 13 NOV 2007
FILE 'STNGUIDE' ENTERED AT 17:05:54 ON 13 NOV 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.06	199.13
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-14.04

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.12	199.19
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-14.04

FILE 'HCAPLUS' ENTERED AT 17:06:48 ON 13 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Nov 2007 VOL 147 ISS 21
FILE LAST UPDATED: 12 Nov 2007 (20071112/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s ((inosine monophosphate dehydrogenase)or(IMPDH)) and interferon

11564 INOSINE
32358 MONOPHOSPHATE
171702 DEHYDROGENASE
629 INOSINE MONOPHOSPHATE DEHYDROGENASE
(INOSINE (W) MONOPHOSPHATE (W) DEHYDROGENASE)
470 IMPDH
79949 INTERFERON

L33 58 ((INOSINE MONOPHOSPHATE DEHYDROGENASE)OR(IMPDH)) AND INTERFERON

=> s ((inosine monophosphate dehydrogenase)or(IMPDH)) and interferon and synerg?

11564 INOSINE
 32358 MONOPHOSPHATE
 171702 DEHYDROGENASE
 629 INOSINE MONOPHOSPHATE DEHYDROGENASE
 (INOSINE (W) MONOPHOSPHATE (W) DEHYDROGENASE)
 470 IMPDH
 79949 INTERFERON
 116923 SYNERG?
 L34 10 ((INOSINE MONOPHOSPHATE DEHYDROGENASE)OR(IMPDH)) AND INTERFERON
 AND SYNERG?

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	2.60	201.79
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-14.04

FILE 'STNGUIDE' ENTERED AT 17:06:50 ON 13 NOV 2007
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
 LAST RELOADED: Nov 9, 2007 (20071109/UP).

=> d l34 1-10 ti

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L34 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Cyclosporin derivatives for the treatment and prevention of hepatitis C infection

L34 ANSWER 2 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon- α

L34 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Treatment of hepatitis V virus (HCV) with subtherapeutic doses of ribavirin

L34 ANSWER 4 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Immunosuppression using the mTOR inhibition mechanism affects replacement of rat liver with transplanted cells

L34 ANSWER 5 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI IMPDH inhibitor combined with vitamin B12 or interferon for treating viral, inflammatory and proliferative diseases

L34 ANSWER 6 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Combined use of inosine monophosphate dehydrogenase (IMPDH) inhibitors with toll-like receptor agonists for immune system activation and treatment of diseases

L34 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI The role of ribavirin in the combination therapy of hepatitis C virus infection

L34 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Combination therapy for RNA virus infections involving ribavirin and
IMPDH inhibitors

L34 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Pleiotropic mechanisms of ribavirin antiviral activities

L34 ANSWER 10 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Dihydroorotate dehydrogenase inhibitors, and use with other agents, for
the treatment of virus-mediated diseases

=> d l34 2 5 7 8 9 10 ti abs bib

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L34 ANSWER 2 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Mycophenolic acid inhibits hepatitis C virus replication and acts in
synergy with cyclosporin A and interferon- α

AB Background & Aims: Chronic hepatitis C virus (HCV) infection is the
leading indication for liver transplantation. Clin. evidence suggests
that particular immunosuppressive agents can have an influence on HCV
recurrence. Cyclosporine A (CsA) specifically inhibits HCV replication
through blocking the viral RNA polymerase enzyme NS5B. In this study, we
investigated the effect of mycophenolic acid (MPA) and other
immunosuppressants on HCV replication. Methods: MPA and other compds.
were tested in vitro using an HCV-replication model containing a luciferase
reporter gene. Results: At clin. relevant concns. (1.0-6.0 μ g/mL), MPA
inhibited HCV replication to approx. 75%. CsA and interferon
(IFN)- α also showed inhibition in a dose-dependent manner. In these
short-term (18 h) expts., MPA did not inhibit cell proliferation or induce
cell death, which could have accounted for the antiviral effect. In
contrast to the antiviral activity of MPA against West Nile virus, the
effect of MPA on HCV replication was guanosine independent. When
combined, MPA and CsA showed significant synergistic inhibition
of replication, reaching maximum inhibition of .apprx.90% at the highest
doses. Synergistic effects were observed with suboptimal concns.
of IFN- α with MPA or CsA. The kinetics of HCV inhibition by MPA,
CsA, and IFN- α were clearly distinct, with earliest effects seen
with IFN- α . No specific inhibitory effects were observed with
tacrolimus or rapamycin. Conclusions: The immunosuppressive drug MPA is
as potent as CsA as an inhibitor of HCV replication. MPA was shown to
have a distinct anti-HCV mechanism of action, independent of cell
proliferation and guanosine depletion.

AN 2006:1324492 HCAPLUS <<LOGINID::20071113>>

DN 146:198108

TI Mycophenolic acid inhibits hepatitis C virus replication and acts in
synergy with cyclosporin A and interferon- α

AU Henry, Scot D.; Metselaar, Herold J.; Lonsdale, Richard C. B.; Kok, Alice;
Haagmans, Bart L.; Tilanus, Hugo W.; Van Der Laan, Luc J. W.

CS Department of Surgery, Erasmus MC-University Medical Center, Rotterdam,
Neth.

SO Gastroenterology (2006), 131(5), 1452-1462

CODEN: GASTAB; ISSN: 0016-5085

PB Elsevier Inc.

DT Journal

LA English

RE.CNT 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 5 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN

TI IMPDH inhibitor combined with vitamin B12 or interferon
for treating viral, inflammatory and proliferative diseases

AB Described are uses of vitamin B12 compound, IMPDH

(inosine-5'-monophosphate dehydrogenase) inhibitor, and optionally an interferon in treatment of viral, inflammatory, immunodeficiency, IMPDH-mediated, and proliferative diseases using. Synergistic in-vitro interactions were observed between (1) α interferon and ribavirin, (2) α interferon and hydroxocobalamin, (3) α interferon, ribavirin and Hydroxocobalamin against bovine viral diarrhea virus as surrogate models of hepatitis C virus (HCV) replication.

AN 2006:101033 HCAPLUS <<LOGINID::20071113>>

DN 144:164240

TI IMPDH inhibitor combined with vitamin B12 or interferon for treating viral, inflammatory and proliferative diseases

IN Cruz, Antonio

PA Transition Therapeutics Inc., Can.

SO PCT Int. Appl., 34 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006010256	A1	20060202	WO 2005-CA1163	20050726
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	EP 1793846	A1	20070613	EP 2005-770301	20050726
	R:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRAI	US 2004-591346P	P	20040726		
	WO 2005-CA1163	W	20050726		

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN

TI The role of ribavirin in the combination therapy of hepatitis C virus infection

AB A review. Ribavirin is a very broad-spectrum anti-viral agent used clin. to treat infections by Lassa fever virus, respiratory syncytial virus (RSV) and, in combination with Interferon- α (IFN- α), hepatitis C virus (HCV). Although it was originally synthesized over 30 yr ago, the precise mechanisms of its therapeutic activities are still not fully understood. Ribavirin was shown to possess both direct and indirect action mechanisms against several DNA and RNA viruses. These include direct inhibition of viral RNA-dependent RNA polymerases, inhibition of the host inosine monophosphate dehydrogenase, modulation of the host immune response and inhibition of viral capping enzymes. More recently, ribavirin was demonstrated to be able to act as an RNA virus mutagen, increasing mutations in the RNA virus genome and reducing their infectivity. Still the real challenge is to identify which of its biol. properties is responsible for the observed clin. efficacy on specific infections. Under this aspect, renewed interest results from its synergistic enhancement of interferon- α (IFN- α) therapy, which could open the way to develop more powerful anti-HCV compds. This work purpose is to provide a broad overview of all the recognized ribavirin action mechanisms against HCV, which can possibly

also explain its synergistic behavior with IFN- α . An overview on the corresponding HCV treatment clin. observations is also provided in the second part of this work.

AN 2004:514481 HCAPLUS <<LOGINID::20071113>>
 DN 141:116272
 TI The role of ribavirin in the combination therapy of hepatitis C virus infection
 AU Picardi, A.; Gentilucci, U. Vespasiani; Zardi, E. M.; D'Avola, D.; Amoroso, A.; Afeltra, A.
 CS Laboratory of Internal Medicine, Hepatology and Immunology, University "Campus Bio-Medico", Rome, Italy
 SO Current Pharmaceutical Design (2004), 10(17), 2081-2092
 CODEN: CPDEFP; ISSN: 1381-6128
 PB Bentham Science Publishers Ltd.
 DT Journal; General Review
 LA English
 RE.CNT 110 THERE ARE 110 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Combination therapy for RNA virus infections involving ribavirin and IMPDH inhibitors
 AB This invention relates to the treatment of viral infections in animals, particularly mammals. Method involves administration of a pharmaceutical composition comprising combinations of antiviral compds. useful for treating viral infections. The anti-viral compds. are combined in such a manner to reduce the detrimental side effects of treatment and to enhance the efficacy. In a particular embodiment, the invention provides a method for treating a viral infection in a mammal comprising administration to a mammal in need of such treatment a therapeutically effective amount of a combination of ribavirin in association with (S)-N-3-[3-(3-methoxy-4-oxazol-5-yl-phenyl)ureido]-benzylcarbamic acid tetrahydrofuran-3-yl-ester and pegylated interferon-alpha-2b.

AN 2003:971807 HCAPLUS <<LOGINID::20071113>>
 DN 140:23206
 TI Combination therapy for RNA virus infections involving ribavirin and IMPDH inhibitors
 IN Malcolm, Bruce A.; Reyes, Gregory R.; Zhou, Sifang
 PA Schering Corporation, USA
 SO PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003101199	A1	20031211	WO 2003-US16891	20030530
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003249659	A1	20031219	AU 2003-249659	20030530
	US 2004034206	A1	20040219	US 2003-449237	20030530
PRAI	US 2002-384658P	P	20020531		
	US 2002-405546P	P	20020822		
	WO 2003-US16891	W	20030530		

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Pleiotropic mechanisms of ribavirin antiviral activities
 AB A review. Renewed interest in the mechanism of action of ribavirin results from its synergistic enhancement of interferon therapy and the need to develop more efficacious agents to treat hepatitis C virus infection. Since the discovery of ribavirin over 30 yr ago by scientists at ICN Pharmaceuticals, many mechanisms of action for ribavirin have been proposed. These include inhibition of host inosine monophosphate dehydrogenase by ribavirin monophosphate, inhibition of viral capping enzymes, inhibition of viral RNA synthesis by ribavirin triphosphate, lethal mutagenesis of viral RNA genomes resulting from promiscuous incorporation of ribavirin triphosphate by the viral RNA polymerase, and modulation of the host immune responses. In this article, we will briefly review the evidence for these mechanisms, emphasizing recent findings. In addition, we will discuss strategies for development of nucleoside analogs that may replace ribavirin in the future.
 AN 2002:941129 HCAPLUS <<LOGINID::20071113>>
 DN 139:78142
 TI Pleiotropic mechanisms of ribavirin antiviral activities
 AU Hong, Zhi; Cameron, Craig E.
 CS Drug Discovery, ICN Pharmaceuticals, Inc., Costa Mesa, CA, 92626, USA
 SO Progress in Drug Research (2002), 59, 41-69
 CODEN: FAZMAE; ISSN: 0071-786X
 PB Birkhaeuser Verlag
 DT Journal; General Review
 LA English
 RE.CNT 141 THERE ARE 141 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 10 OF 10 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Dihydroorotate dehydrogenase inhibitors, and use with other agents, for the treatment of virus-mediated diseases
 AB Flavivirus, rhabdovirus, and paramyxovirus infections may be treated by administering an inhibitor of dihydroorotate dehydrogenase, e.g. 6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarboxylic acid sodium salt (Brequinar). A synergistic effect can be obtained if an interferon, e.g. interferon $\alpha 2$, interferon $\alpha 8$ or interferon β , or an inhibitor of a second enzyme selected from inosine monophosphate dehydrogenase, guanosine monophosphate synthetase, cytidine triphosphate synthetase and S-adenosylhomocysteine hydrolase, is also administered. Compound preparation is described.
 AN 2001:265241 HCAPLUS <<LOGINID::20071113>>
 DN 134:290390
 TI Dihydroorotate dehydrogenase inhibitors, and use with other agents, for the treatment of virus-mediated diseases
 IN Tan, Yin Hwee; Driscoll, John Stanford; Mui Mui, Sim
 PA Institute of Molecular and Cell Biology, Singapore; Mui Mui, Sim
 SO PCT Int. Appl., 50 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001024785	A2	20010412	WO 2000-US26797	20000929
	WO 2001024785	A3	20020711		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				

	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,	
	CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
EP 1237546	A2	20020911 EP 2000-965517 20000929
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,	
	IE, SI, LT, LV, FI, RO, MK, CY, AL	
JP 2003510352	T	20030318 JP 2001-527784 20000929
US 6841561	B1	20050111 US 2002-89553 20020508
PRAI US 1999-157017P	P	19991001
WO 2000-US26797	W	20000929
OS MARPAT 134:290390		